mal recessive LGMD from the 1950s on, Fardeau and colleagues, in 1989, described an autosomal recessive LGMD on the French island of Réunion; in 1991, this disorder was found to link to chromosome 15q, and in 1995, it was identified as calpainopathy. 6 In 1986, a report of autosomal dominant LGMD established the genetic heterogeneity of this syndrome. 7 A subsequent family with autosomal dominant LGMD reported in 1988 was found to have a type of LGMD that linked to chromosome 5q in 1992, and in 2000, this family was identified as having a mutation in the myotilin gene. 8 
A genetic classification of
LGMDs was proposed in 1995, based on the inheritance pattern: Type 1 LGMDs are autosomal dominant, and type 2 LMG-MDs are autosomal recessive. A letter defining the order of discovery of the chromosomal locus is appended to the numeric designation. 9 The list of LGMDs with known genetic loci continues to grow rapidly (8 autosomal dominant LGMDs [LGMD1A-1H) and 23 autosomal recessive LGMDs [LGMD2A-2W]). 10 A definitive diagnosis of the type of LGMD is important; it avoids repeated testing or empirical, potentially toxic treatments for acquired causes such as inflammatory myopathy; provides patients with a sense of closure; assists genetic counseling; and aids the identification and treatment of complications. 11 In the future, knowledge of the underlying genetic mutation will be necessary for enrollment in clinical trials of targeted therapies. However, the genetic heterogeneity of the LGMD phenotype makes establishing a definitive diagnosis challenging. The approach to diagnosis is complex and includes evaluation of the inheritance pattern and identification of specific clinical features that direct further testing. 11 Conventional genetic testing for mendelian disorders such as LGMD involve genome-wide linkage to identify mutations that cosegregate within affected individuals, positional cloning, and, finally, targeted candidate gene sequencing. 12 In autosomal recessive disorders, autozygosity mapping, which identifies regions of the genome that are homozygous in affected individuals but not in unaffected family members, is followed by gene sequencing to identify the causal mutation. 13 These techniques assume the availability of several affected family members and are of limited utility when only a few cases are available or in sporadic cases owing to de novo mutations. In addition, genetic and phenotypic heterogeneity and incomplete penetrance limit these approaches. 13 The DNA sequencing technique described by Sanger et al 14 was used to sequence the human genome in 2001 (the Human Genome Project). 15 In 2004, next-generation sequencing methods (which use high-throughput, massively parallel sequencing platforms) were introduced, making it possible to sequence sev- eral thousand or more fragments of DNA simultaneously. Nextgeneration sequencing platforms can complete genome sequencing within a few weeks at a fraction of the cost of Sanger sequencing. In addition to whole-genome sequencing, next-generation sequencing can be used for whole-exome sequencing (WES). The exome is the sequence of all exons of protein-coding genes, covering 1% to 2% of the genome, and contains an estimated 85% of the mutations that cause mendelian disorders. 16 Hence, WES, or targeted sequencing of all known exons, is often sufficient to identify the genes underlying mendelian disorders. In WES, genomic DNA is first extracted and broken down into short segments. Priming sequences of DNA are added to the ends of these fragments. The fragments are then captured by mixing them with probes that are complementary to known exons in the genome. The remaining DNA is washed away, leaving the enriched exome sequences for amplification and massive parallel sequencing. Fluorescent nucleotides incorporated into strands of DNA during the sequencing process are detected using laser activation. Millions of short sequence reads are mapped to a reference genome, and variants within the genome are identified. 12, 17 These variants are then filtered to exclude nonpathogenic polymorphisms. The first step is to crossreference the variants against publicly available databases of exomes from unaffected individuals. The remaining variations are then filtered by the mode of inheritance, segregation within affected family members, stratification, etc. 17 In this issue of JAMA Neurology, Ghaoui and colleagues 18 describe the application of WES to evaluate patients whose LGMD subtype remained undiagnosed after immunohistochemistry of muscle biopsy specimens and targeted Sanger sequencing, which provided a diagnosis for 83 of 237 families (35%). Of the remaining 154 families, 100 individuals from 60 families underwent WES. Ghaoui et al 18 identified pathogenic mutations in 27 of 60 families (45%). Importantly, they studied 45 probands without parental DNA, in whom the diagnostic rate of WES was a respectable 40%, underscoring the value of this technique in sporadic cases. Twelve families had a known LGMD-related gene mutation. Six of these represented previously reported mutations; it is unclear why these were missed by candidate gene testing.
More interestingly, 14 of 60 families had mutations in genes that are not classically associated with an LGMD phenotype (GTDC2, LAMA2, and ACTA1), congenital myasthenia due to DOK7 mutation, or even metabolic myopathy (PYGM and CPT2).
A second look at the phenotype helped confirm the diagnosis in several cases: clinical features missed at initial examination (contractures, scoliosis, follicular hyperkeratosis and keloids in Bethlem myopathy, low-set ears in STIM1-related myopathy with tubular aggregates, and fatigability in congenital myasthenia), review of muscle biopsy (reduced collagen staining, reduced protein detected on immunohistochemistry and Western blot, and absence of enzyme detected on histochemistry), magnetic resonance imaging of the limbs for patterns of muscle atrophy or magnetic resonance imaging of the brain for white matter disease. In 1 family, a novel heterozygous variant in the CHD7 gene was detected. The proband had proximal upper extremity weakness and scapular winging with mild myopathy detetected in biopsy specimen. Other phenotypic features of CHARGE syndrome (coloboma, heart defect, atresia of the choanae, retarded growth, and genital abnormalities) were not present, but low-set ears and magnetic resonance imaging evidence of hypoplasia of the semicircular canals were noted (ear abnormalities).
This study 18 supports the utility of WES for the genetic diagnosis of LGMD. However, important ethical considerations include informed consent and the management of clinically important, unrelated genetic information that may be incidentally uncovered. Ghaoui et al 18 correctly point out the limitations of WES; incomplete enrichment or "coverage" of the sequences of interest is one limitation. As a consequence, a sequencing error may be falsely interpreted as a mutation, or a true mutation may be missed. Similarly, slight misalignment of the sequenced DNA to the reference genome may cause small base substitutions or insertions/deletions to be missed, or create the impression of new mutations. 17 Because the DNA probes are based on sequences from known exons, mutations in unknown exons will be missed. Pathogenic mutations in noncoding elements, introns, regulatory elements such as promoters and enhancers, or splice site mutations will also not be detected. 16 Repeat expansions are generally not detected with exome sequencing, and Ghaoui et al 18 appropriately excluded type 2 myotonic dystrophy and type 1 facioscapulohumeral muscular dystrophy prior to WES in their study. Finally, filtering techniques may erroneously omit pathogenic mutations because mutation carriers who have not yet expressed the disease owing to reduced penetrance may be present in the control databases. 17 Where, then, does the clinical armamentarium of the traditional neurologist fit in? Is it time to replace the phenotypic classification with a genetic classification of muscular dystrophies? A recent report of the National Academy of Sciences recommends a new, dynamic taxonomy of human diseases incorporating molecular biology, clinical data, and environmental data to improve health care. 19 The influence of yet-to-be discovered epigenetic factors on disease expression must also be considered. The genetic diagnosis of muscular dystrophies is rapidly evolving; the jury is still out on the optimal diagnostic algorithms and techniques and their clinical and genetic implications. Close attention to clinical examination incorporating not only the neurologic examination but also a detailed multisystem examination remains an essential part of the diagnostic algorithm in muscular dystrophy. Long-term follow-up will provide valuable phenotypegenotype correlations for management of future patients. It is not yet time to retire our reflex hammers. 
